Skip to main content
main-content

01.12.2017 | Research | Ausgabe 1/2017 Open Access

Radiation Oncology 1/2017

Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors

Zeitschrift:
Radiation Oncology > Ausgabe 1/2017
Autoren:
Yukiko Nishikawa, Koichi Yasuda, Shozo Okamoto, Yoichi M. Ito, Rikiya Onimaru, Tohru Shiga, Kazuhiko Tsuchiya, Shiro Watanabe, Wataru Takeuchi, Yuji Kuge, Hao Peng, Nagara Tamaki, Hiroki Shirato
Wichtige Hinweise

Electronic supplementary material

The online version of this article doi: (10.​1186/​s13014-017-0886-9) contains supplementary material, which is available to authorized users.

Abstract

Background

Hypoxic cancer cells are thought to be radioresistant and could impact local recurrence after radiotherapy (RT). One of the major hypoxic imaging modalities is [18F]fluoromisonidazole positron emission tomography (FMISO-PET). High FMISO uptake before RT could indicate radioresistant sites and might be associated with future local recurrence. The predictive value of FMISO-PET for intra-tumoral recurrence regions was evaluated using high-resolution semiconductor detectors in patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy (IMRT).

Methods

Nine patients with local recurrence and 12 patients without local recurrence for more than 3 years were included in this study. These patients received homogeneous and standard doses of radiation to the primary tumor irrespective of FMISO uptake. The FMISO-PET image before RT was examined via a voxel-based analysis, which focused on the relationship between the degree of FMISO uptake and recurrence region.

Results

In the pretreatment FMISO-PET images, the tumor-to-muscle ratio (TMR) of FMISO in the voxels of the tumor recurrence region was significantly higher than that of the non-recurrence region (p < 0.0001). In the recurrent patient group, a TMR value of 1.37 (95% CI: 1.36–1.39) corresponded to a recurrence rate of 30%, the odds ratio was 5.18 (4.87–5.51), and the area under the curve (AUC) of the receiver operating characteristic curve was 0.613. In all 21 patients, a TMR value of 2.42 (2.36–2.49) corresponded to an estimated recurrence rate of 30%, and the AUC was only 0.591.

Conclusions

The uptake of FMISO in the recurrent region was significantly higher than that in the non-recurrent region. However, the predictive value of FMISO-PET before IMRT is not sufficient for up-front dose escalation for the intra-tumoral high-uptake region of FMISO. Because of the higher mean TMR of the recurrence region, a new hypoxic imaging method is needed to improve the sensitivity and specificity for hypoxia.
Zusatzmaterial
Additional file 1: Table S1. The prescribed doses to the PTVs. Abbreviations: PTV planning target volume, D XX% the maximum dose covering the target volume of XX%, V XXGy the percent of the target volume receiving XXGy. (DOCX 40 kb)
13014_2017_886_MOESM1_ESM.docx
Additional file 2: Table S2. The dose constraints to organs at risk (OARs). Abbreviations: OAR organ at risk, PRV planning organ at risk volume, D XX% the maximum dose covering the target volume of XX%, D 1cc the maximum dose covering the target volume of 1 cm3, V XXGy the percent of the target volume receiving XXGy, D max maximum dose, D mean mean dose, D median median dose. (DOCX 47 kb)
13014_2017_886_MOESM2_ESM.docx
Additional file 3: Table S3. Chemotherapy used in each patient. Abbreviations: TPF Docetaxel, Cisplatin and Fluorouracil, S-1 Tegafur/Gimeracil/Oteracil, CDDP Cisplatin, FP Fluorouracil and Cisplatin. (DOCX 57 kb)
13014_2017_886_MOESM3_ESM.docx
Additional file 4: Figure S1. The representative plane images before RT and at recurrence of all recurrent patients. Yellow line indicated primary tumor before RT, and red line indicated recurrence tumor. Abbreviations: RT radiation therapy. (PNG 1004 kb)
13014_2017_886_MOESM4_ESM.png
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Radiation Oncology 1/2017 Zur Ausgabe


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise